## **Electronic supplementary information**

## Journal name: BioDrugs

## Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized Phase 3 trial

Chang-Hee Suh, Dae Hyun Yoo, Alfredo Berrocal Kasay, Elias Chalouhi El-Khouri, Francisco FidencioCons Molina, Pavel Shesternya, Pedro Miranda, Francisco G. Medina-Rodriguez, Piotr Wiland, Slawomir Jeka, Jose Chavez-Corrales, Thomas Linde, Pawel Hrycaj, Mauricio Abello-Banfi, Ihor Hospodarskyy, Janusz Jaworski, Mariusz Piotrowski, Marek Brzosko, Marek Krogulec, Sergii Shevchuk, Armando Calvo, Daina Andersone, Won Park, Seung Cheol Shim, Sang Joon Lee, Sung Young Lee.

**Corresponding author:** Professor Dae Hyun Yoo, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. Email: dhyoo@hanyang.ac.kr

Table S1 Mean scores and change from baseline in ACR individual components (efficacy
population <sup>a</sup> )

	CT-P10		US-RTX		EU	RTX	Combined RTX <sup>b</sup>		
	(n=	:155)	(n=144)		(n= <b>59</b> )		(n=203)		
	Actual	Change	Actual	Change	Actual	Change	Actual	Change	
	result	from	result	from	result	from	result	from	
		baseline		baseline		baseline		baseline	
Number of	tender jo	oints							
Baseline	22.2		21.2		22.1		21.5		
Week 24	7.2	-14.7	6.8	-14.3	8.8	-13.3	7.4	-14.0	
Week 48	5.9	-16.5	5.2	-15.8	6.9	-14.3	5.7	-15.4	
Number of	swollen j	oints							
Baseline	15.1		13.9		15.2		14.3		
Week 24	3.3	-11.5	3.5	-10.4	5.6	-9.6	4.1	-10.1	
Week 48	2.5	-12.6	2.5	-11.3	4.0	-10.3	3.0	-11.0	
Patient's as	ssessment	t of pain us	sing VAS						
Baseline	70.4		69.3		72.7		70.3		
Week 24	32.8	-36.7	31.9	-37.1	34.3	-38.4	32.6	-37.5	
Week 48	29.6	-39.7	32.1	-36.6	28.7	-43.8	31.1	-38.8	
Patient's g	lobal asse	essment of	disease a	ctivity usi	ng VAS				
Baseline	68.9		68.6		71.8		69.5		
Week 24	33.4	-35.1	32.2	-35.9	34.4	-37.3	32.9	-36.4	
Week 48	29.7	-38.4	31.6	-36.6	28.9	-42.6	30.8	-38.4	
Physician's global assessment of disease activity using VAS									

Baseline	65.2		64.4		66.1		64.9	
Week 24	25.4	-39.3	23.4	-41.1	39.7	-36.1	25.3	-39.6
Week 48	20.3	-44.4	21.1	-43.5	22.9	-43.0	21.6	-43.3
HAQ estim	ate of ph	ysical abil	ity					
Baseline	1.73		1.67		1.69		1.67	
Week 24	1.04	-0.65	1.11	-0.54	1.11	-0.57	1.11	-0.55
Week 48	0.98	-0.70	1.04	-0.59	0.96	-0.71	1.02	-0.63
CRP, mg/d	L							
Baseline	2.2		2.3		3.4		2.6	
Week 24	1.0	-1.2	1.0	-1.2	1.3	-2.2	1.1	-1.5
Week 48	0.6	-1.5	1.1	-1.2	0.9	-2.4	1.0	-1.5
ESR, mm/h	1							
Baseline	55.1		56.4		59		203	
Week 24	32.4	-23.8	33.2	-23.4	32.7	-18.8	33.0	-22.0
Week 48	29.0	-27.0	32.8	-24.4	25.8	-25.6	30.8	-24.7

ACR American College of Rheumatology, CRP C-reactive protein, ESR erythrocyte sedimentation rate, EU European Union, HAQ Health Assessment Questionnaire, RTX rituximab, US United States, VAS visual analogue scale

<sup>a</sup>Week 48 data are from the efficacy population–2<sup>nd</sup> treatment course subset (CT-P10, n=139; US-RTX, n=135; EU-RTX, n=53; Combined RTX, n=193). <sup>b</sup>US-RTX and EU-RTX groups combined.

	<b>CT-P10</b>		US-RTX		EU-RTX		Combined RTX <sup>b</sup>		
		(n=155)		(n=144)		(n=59)		(n=203)	
	n	Mean (SD)	n	Mean (SD)	n	Mean (SD)	n	Mean (SD)	
DAS28-ESR	2								
Week 24									
FcγRIIa sul	otype								
RR	23	-2.6 (1.2)	15	-1.9 (1.0)	9	-2.6 (0.9)	24	-2.2 (1.0)	
HR+HH	99	-2.6 (1.1)	108	-2.7 (1.1)	40	-2.3 (1.3)	148	-2.6 (1.2)	
FcγRIIIa su	ıbtype	2							
FF	66	-2.6 (1.1)	53	-2.6 (1.3)	23	-2.6 (1.3)	76	-2.6 (1.3)	
FV+VV	50	-2.6 (1.2)	69	-2.6 (1.0)	25	-2.0 (1.4)	94	-2.4 (1.1)	
Week 48									
FcγRIIa sul	otype								
RR	21	-3.0 (1.6)	15	-2.3 (1.7)	9	-3.0 (1.0)	24	-2.6 (1.5)	
HR+HH	95	-2.9 (1.2)	101	-2.9 (1.4)	38	-3.0 (1.4)	139	-2.9 (1.4)	
FcγRIIIa su	ıbtype	e							
FF	62	-2.9 (1.3)	49	-2.9 (1.5)	22	-3.3 (1.4)	71	-3.0 (1.5)	
FV+VV	48	-3.0 (1.3)	66	-2.8 (1.4)	24	-2.7 (1.2)	90	-2.7 (1.3)	
DAS28-CRI	)								
Week 24									
FcγRIIa sul	otype								
RR	23	-2.3 (1.2)	15	-1.7 (1.2)	9	-2.4 (0.8)	24	-2.0 (1.1)	
HR+HH	98	-2.4 (1.0)	108	-2.4 (1.1)	40	-2.2 (1.4)	148	-2.4 (1.2)	

## **Table S2** Change from baseline in DAS28 by FcγR subtypes (efficacy population<sup>a</sup>)

Suh et al 2018

FcyRIIIa subtype

FF	66	-2.4 (1.2)	53	-2.2 (1.3)	23	-2.5 (1.3)	76	-2.3 (1.3)
FV+VV	49	-2.3 (1.2)	69	-2.4 (1.0)	25	-2.0 (1.3)	94	-2.3 (1.1)
Week 48								
FcyRIIa sul	btype							
RR	21	-2.6 (1.3)	15	-2.3 (1.7)	9	-2.8 (0.8)	24	-2.4 (1.4)
HR+HH	94	-2.7 (1.1)	100	-2.6 (1.3)	38	-2.7 (1.4)	138	-2.7 (1.3)
FcγRIIIa sι	ıbtype	;						
FF	62	-2.6 (1.0)	49	-2.6 (1.3)	22	-3.0 (1.4)	71	-2.7 (1.4)
FV+VV	47	-2.7 (1.3)	65	-2.6 (1.3)	24	-2.4 (1.2)	89	-2.5 (1.3)

*CRP* C-reactive protein, *DAS28* Disease Activity Score using 28 joints, *ESR* erythrocyte sedimentation rate, *EU* European Union,  $Fc\gamma R$  Fc gamma receptor, *RTX* rituximab, *SD* standard deviation, *US* United States

<sup>a</sup>Week 48 data are from the efficacy population–2<sup>nd</sup> treatment course subset (CT-P10, n=139; US-RTX, n=135; EU-RTX, n=53; Combined RTX, n=193). <sup>b</sup>US-RTX and EU-RTX groups combined.

Parameter (unit)	CT-P10	US-RTX	EU-RTX
(PK population)			
	n=154	n=147	n=59
Cmax 1st course (µg/mL), n	151	146	59
Mean (CV)	438.0 (24.2)	432.6 (27.5)	474.2 (21.2)
Cmax 1, 1st course (µg/mL), n	153	146	59
Mean (CV)	361.6 (25.1)	373.8 (21.9)	394.3 (20.2)
Cmin W24 (µg/mL), n	136	135	56
Mean (CV)	6.0 (716.1)	6.0 (635.9)	0.5 (162.2)
Ctrough 1st course ( $\mu g/mL$ )	153	146	59
Mean (CV)	75.4 (68.4)	84.7 (80.8)	81.8 (67.3)
T <sub>max 1st course</sub> (h)	153	147	59
Modion (min mov)	339.7	339.6	339.3
Median (min, max)	(4.3, 557.0)	(4.5, 367.3)	(4.5, 346.5)
(PK population -2nd	n=141	n=137	n=57
treatment course subset)	11-141	II-137	II-37
Cmax 2nd course (µg/mL), n	141	137	57
Mean (CV)	418.9 (29.3)	420.3 (29.5)	464.5 (23.9)
Cmax 1, 2nd course (µg/mL),	1.4.1	100	57
n	141	136	57
Mean (CV)	353.0 (25.8)	350.3 (27.9)	382.2 (23.1)
C <sub>min</sub> w48 (µg/mL), n	138	132	55
Mean (CV)	4.4 (784.2)	1.0 (169.8)	2.1 (354.5)

**Table S3** Secondary pharmacokinetic parameters up to Week 48 (PK population)

Ctrough 2nd course ( $\mu g/mL$ ),	141	136	57
n		150	27
Mean (CV)	83.0 (76.2)	80.1 (51.7)	88.3 (51.2)
Tmax 2nd course (h)	141	137	57
Medice (min mor)	339.8	339.9	339.7
Median (min, max)	(0.0, 4152.2)	(4.3, 4125.0)	(4.6, 411.8)

 $C_{max \ lst \ course}$  maximum concentration after the second infusion in the 1st treatment course,  $C_{max \ l, \ lst \ course}$ maximum concentration after the first infusion in the 1st treatment course,  $C_{max \ 2nd \ course}$  maximum concentration after the second infusion in the 2nd treatment course,  $C_{max \ l, \ 2nd \ course}$  maximum concentration after the first infusion in the 2nd treatment course,  $C_{min \ W24}$  predose concentration at Day 168 (Week 24),  $C_{min \ W48}$  predose concentration at Day 336 (Week 48),  $C_{trough \ 1st \ course}$  predose concentration at Day 14 (Week 2 prior to second infusion),  $C_{trough \ 2nd \ course}$  predose concentration at Day 182 (Week 26 prior to second infusion), CV coefficient of variation, EU European Union, PKpharmacokinetic, RTX=rituximab,  $T_{max \ 1st \ course}$  time to maximum concentration in the 1st treatment course,  $T_{max \ 2nd \ course}$  time to maximum concentration in the 2nd treatment course, US United States

	<b>CT-P10</b>	US-RTX	EU-RTX	Combined	Total	
	(n=161)	(n=151)	(n=60)	RTX	(n=372)	
System organ class				(n=211)		
Preferred term		Numbe	er (%) of pa	tients		
Total number of AEs	350	294	96	390	740	
Total mation to with N1 AF	125 (77 ()	07((4.2))	39	126 (64 5)	2(1(70.2))	
Total patients with ≥1 AE	125 (77.6)	97 (64.2)	(65.0)	136 (64.5)	261 (70.2)	
Infastions and infastations	(2)(29,5)	54 (25 9)	17	71 (22 ()	122 (25 9)	
Infections and infestations	62 (38.5)	54 (35.8)	(28.3)	71 (33.6)	133 (35.8)	
Upper respiratory tract	24(14.0)	20 (10 0)	0 (15 0)	20 (19 5)	62(160)	
infection	24 (14.9)	30 (19.9)	9 (15.0)	39 (18.5)	63 (16.9)	
Urinary tract infection	15 (9.3)	8 (5.3)	2 (3.3)	10 (4.7)	25 (6.7)	
Lower respiratory tract	10 (6 2)	<b>9</b> (5 2)	2 (5 0)	11 (5 2)	21 (5.6)	
infection	10 (6.2)	8 (5.3)	3 (5.0)	11 (5.2)	21 (3.0)	
Rhinitis	3 (1.9)	6 (4.0)	1 (1.7)	7 (3.3)	10 (2.7)	
Influenza	2 (1.2)	0 (0.0)	2 (3.3)	2 (0.9)	4 (1.1)	
Injury, poisoning, and	12 (26 7)	22 (15 2)	14	27 (17 5)	90 (21 5)	
procedural complications	43 (26.7)	23 (15.2)	(23.3)	37 (17.5)	80 (21.5)	
Infining selected secretions	22 (20 5)	12 (7.0)	13	<b>75</b> (11 0)	50 (15 ()	
Infusion-related reaction	33 (20.5)	12 (7.9)	(21.7)	25 (11.8)	58 (15.6)	
Fracture	4 (2.5)	6 (4.0)	1 (1.7)	7 (3.3)	11 (3.0)	
Injury	4 (2.5)	5 (3.3)	0 (0.0)	5 (2.4)	9 (2.4)	
Gastrointestinal disorders	17 (10.6)	19 (12.6)	7 (11.7)	26 (12.3)	43 (11.6)	

**Table S4** Adverse events reported in >3% of patients in any group (safety population)

Abdominal pain	4 (2.5)	5 (3.3)	1 (1.7)	6 (2.8)	10 (2.7)
Musculoskeletal and connective tissue disorders	20 (12.4)	14 (9.3)	5 (8.3)	19 (9.0)	39 (10.5)
Back pain	5 (3.1)	4 (2.6)	1 (1.7)	5 (2.4)	10 (2.7)
Investigations	18 (11.2)	16 (10.6)	3 (5.0)	19 (9.0)	37 (9.9)
Alanine aminotransferase increased	5 (3.1)	7 (4.6)	0 (0.0)	7 (3.3)	12 (3.2)
Nervous system disorders	14 (8.7)	13 (8.6)	2 (3.3)	15 (7.1)	29 (7.8)
Headache	8 (5.0)	8 (5.3)	2 (3.3)	10 (4.7)	18 (4.8)
Metabolism and nutrition disorders	16 (9.9)	10 (6.6)	2 (3.3)	12 (5.7)	28 (7.5)
Hypertriglyceridemia	7 (4.3)	4 (2.6)	1 (1.7)	5 (2.4)	12 (3.2)
Skin and subcutaneous tissue disorders	11 (6.8)	9 (6.0)	4 (6.7)	13 (6.2)	24 (6.5)
Pruritus <sup>a</sup>	3 (1.9)	1 (0.7)	3 (5.0)	4 (1.9)	7 (1.9)
Blood and lymphatic system disorders	10 (6.2)	10 (6.6)	4 (6.7)	14 (6.6)	24 (6.5)
Anemia	6 (3.7)	5 (3.3)	2 (3.3)	7 (3.3)	13 (3.5)
Vascular disorders	8 (5.0)	7 (4.6)	0 (0.0)	7 (3.3)	15 (4.0)
Hypertension	6 (3.7)	4 (2.6)	0 (0.0)	4 (1.9)	10 (2.7)
Psychiatric disorders	4 (2.5)	4 (2.6)	3 (5.0)	7 (3.3)	11 (3.0)
Depression	1 (0.6)	1 (0.7)	2 (3.3)	3 (1.4)	4 (1.1)

AE adverse event, EU European Union, RTX rituximab, US United States

Note: The total number of AEs included all patient events. At each level of summarization, a patient was counted only once if they reported one or more events. Only the most severe event was counted.

System organ classes were arranged by decreasing total percentage, and system organ class and combined preferred terms were coded using Medical Dictionary for Regulatory Activities (MedDRA), Version 18.1

<sup>a</sup>Out of the seven pruritus cases, five cases occurred at least two weeks after the last infusion date of study drug. Two pruritus cases (both from the CT-P10 group) occurred within two weeks after the last infusion date of study drug, but both cases were considered unrelated to the study drug by the investigator.

	CT-P10	US-RTX	EU-RTX	Combined	Total	
	(n=161)	(n=151)	(n=60)	RTX	(n=372)	
System organ class				(n=211)		
Preferred term		Numb	er (%) of ]	patients		
Total number of SAEs	14	16	4	20	34	
Total patients with at least 1 SAE	13 (8.1)	14 (9.3)	4 (6.7)	18 (8.5)	31 (8.3)	
Injury, poisoning, and procedural	4 (2 5)	1 ( <b>)</b> ()a	0 (0 0)	4 (1 0)	<b>e</b> ( <b>1 1</b> )	
complications	4 (2.5)	4 (2.6) <sup>a</sup>	0 (0.0)	4 (1.9)	8 (2.2)	
Fracture	4 (2.5)	2 (1.3)	0 (0.0)	2 (0.9)	6 (1.6)	
Injury	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.9)	2 (0.5)	
Joint dislocation	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.5)	1 (0.3)	
Infections and infestations	2 (1.2)	4 (2.6)	0	4 (1.9)	6 (1.6)	
Cellulitis	1 (0.6)	1 (0.7) <sup>b</sup>	0 (0.0)	1 (0.5)	2 (0.5)	
Localized infection	0 (0.0)	1 (0.7) <sup>b</sup>	0 (0.0)	1 (0.5)	1 (0.3)	
Lower respiratory tract infection	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.5)	1 (0.3)	
Pneumonia	1 (0.6)	1 (0.7) <sup>b</sup>	0 (0.0)	1 (0.5)	2 (0.5)	
Blood and lymphatic system						
disorders	1 (0.6)	1 (0.7)	1 (1.7)	2 (0.9)	3 (0.8)	
Leukopenia	0 (0.0)	0 (0.0)	1 (1.7) <sup>b</sup>	1 (0.5)	1 (0.3)	
Pancytopenia	1 (0.6)	1 (0.7) <sup>b</sup>	0 (0.0)	1 (0.5)	2 (0.5)	
Neoplasms benign, malignant,						
	0 (0.0)	2 (1.3)	3 (5.0)	5 (2.4)	5 (1.3)	

**Table S5** Serious adverse events reported in any group (safety population)

Adenocarcinoma of colon	0 (0.0)	0 (0.0)	1 (1.7)	1 (0.5)	1 (0.3)
Bladder cancer	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.5)	1 (0.3)
Breast cancer	0 (0.0)	1 (0.7)	1 (0.7)	2 (0.9)	2 (0.5)
Lymphangioma	0 (0.0)	0 (0.0)	1 (1.7)	1 (0.5)	1 (0.3)
Gastrointestinal disorders	0 (0.0)	2 (1.3)	0 (0.0)	2 (0.9)	2 (0.5)
Colitis ischemic	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.5)	1 (0.3)
Intestinal obstruction	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.5)	1 (0.3)
Hepatobiliary disorders	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.5)
Cholecystitis	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Cholelithiasis	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Musculoskeletal and connective	1 (0, ()	1 (0.7)	0 (0 0)	1 (0 5)	2 (0 5)
tissue disorders	1 (0.6)	1 (0.7)	0 (0.0)	1 (0.5)	2 (0.5)
Arthralgia	0 (0.0)	1 (0.7) <sup>b</sup>	0 (0.0)	1 (0.5)	1 (0.3)
Hand deformity	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Nervous system disorders	1 (0.6)	1 (0.7)	0 (0.0)	1 (0.5)	2 (0.5)
Tremor	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Vertebrobasilar insufficiency	0 (0.0)	1 (0.7)	0 (0.0)	1 (0.5)	1 (0.3)
General disorders and	1 (0 ()	0 (0 0)	0 (0 0)	0 (0 0)	1 (0 2)
administration site conditions	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Chest pain	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Renal and urinary disorders	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Acute kidney injury	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Respiratory, thoracic and	1 (0, ()	0 (0 0)	0 (0 0)	0 (0 0)	1 (0.2)
mediastinal disorders	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Dyspnea exertional	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)


EU European Union, RTX rituximab, SAE serious adverse event, US United States

Note: The total number of AEs included all patient events. At each level of summarization, a patient was counted only once if they reported one or more events. Only the most severe event was counted. System organ classes were arranged by decreasing total percentage, and system organ class and combined preferred terms were coded using Medical Dictionary for Regulatory Activities (MedDRA), Version 18.1.


<sup>a</sup>One patient had 2 SAEs (fracture and joint dislocation). <sup>b</sup>Cases related to the study drug.

Fig. S1 Mean change from baseline in disease activity

(a) DAS28-ESR, (b) DAS28-CRP over 48 weeks in the CT-P10, US-RTX and EU-RTX groups (efficacy population <sup>a</sup>).




*CRP* C-reactive protein, *DAS28* Disease Activity Score using 28 joint counts, *ESR* erythrocyte sedimentation rate, *EU* European Union, *RTX* rituximab, *SD* standard deviation, *US* United States <sup>a</sup> Data after Week 24 are from the efficacy population–2<sup>nd</sup> treatment course subset.



**Fig. S2** Proportion of patients achieving clinical response at 24 and 48 weeks (efficacy population<sup>a</sup>)

*ACR* American College of Rheumatology, *EU* European Union, *RTX* rituximab, *US* United States <sup>a</sup>Week 48 data are from the efficacy population–2<sup>nd</sup> treatment course subset.




**Fig. S3** EULAR response at Weeks 24 and 48 (efficacy population <sup>a</sup>)

EULAR European League Against Rheumatism, RTX rituximab

<sup>a</sup>Week 48 data are from the efficacy population–2<sup>nd</sup> treatment course subset.


**Fig. S4** Mean clinical disease activity index (CDAI) score (a) and mean simplified disease activity index (SDAI) score (b) (efficacy population <sup>a</sup>)



*CDAI* clinical disease activity index, *EU* European Union, *RTX* rituximab, *SDAI* simplified disease activity index, US=United States

<sup>a</sup>Week 32, week 40, and week 48 data are from the efficacy population–2<sup>nd</sup> treatment course subset.

**Fig. S5** Cumulative probability distribution of joint damage progression (efficacy population) (a) total score, (b) Total erosion score, (c) Total JSN score.



JSN joint space narrowing, RTX rituximab